4-Ethoxy-7,9-dimethyl-8-(4-nitrobenzyl)-2-piperazin-1-yl-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine → 8-(4-Aminobenzyl)-4-ethoxy-7,9-dimethyl-2-piperazin-1-yl-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine
반응식
[OH-].[NH3+]N.[CH2:4]([O:6][C:7]1[C:8]2[S:21][C:20]3[N:22]=[C:23]([CH3:37])[C:24]([CH2:27][C:28]4[CH:33]=[CH:32][C:31]([N+:34]([O-])=O)=[CH:30][CH:29]=4)=[C:25]([CH3:26])[C:19]=3[C:9]=2[N:10]=[C:11]([N:13]2[CH2:18][CH2:17][NH:16][CH2:15][CH2:14]2)[N:12]=1)[CH3:5]>C(O)C.[Pd]>[NH2:34][C:31]1[CH:32]=[CH:33][C:28]([CH2:27][C:24]2[C:23]([CH3:37])=[N:22][C:20]3[S:21][C:8]4[C:7]([O:6][CH2:4][CH3:5])=[N:12][C:11]([N:13]5[CH2:18][CH2:17][NH:16][CH2:15][CH2:14]5)=[N:10][C:9]=4[C:19]=3[C:25]=2[CH3:26])=[CH:29][CH:30]=1참가 물질
5
반응물 2
생성물 1
시약·촉매·용매 2
실험 절차
40 mg 10% Pd/C and 0.5 ml (10 mmol) hydraziniumhydroxide are added to 0.36 g (0.8 mmol) 4-ethoxy-7,9-dimethyl-8-(4-nitrobenzyl)-2-piperazin-1-yl-pyrido[3′,2′:4,5]thieno[3,2-d]pyrimidine in 3 ml ethanol. Then, refluxing is carried for 10 h, the solvent is removed and the residue is taken up with 50 ml chloroform. Following filtration, the solvent is removed and the residue is recrystallized from chloroform/cyclohexane. 0.16 g (45%) of the title substance is obtained.
후처리
- temperatureThen, refluxing
- customthe solvent is removed
- filtrationfiltration
- customthe solvent is removed
- customthe residue is recrystallized from chloroform/cyclohexane
- custom0.16 g (45%) of the title substance is obtained
출처 및 근거
- ORD 기록
- ord-a2020dcb98cf4e7abd4ee502d174d483
- 출처 데이터셋
- uspto-grants-2011_11
- 특허 번호
- US08058285B2
반응 노트
불러오는 중…